Swedish Orphan Biovitrum AB (publ) (FRA:B6E)
Germany · Delayed Price · Currency is EUR | Market Cap | 14.76B +61.7% |
| Revenue (ttm) | 2.77B +13.5% |
| Net Income | 124.81M -68.4% |
| EPS | 0.36 -68.6% |
| Shares Out | n/a |
| PE Ratio | 118.22 |
| Forward PE | 19.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 42.38 |
| Previous Close | 40.76 |
| Day's Range | 42.38 - 42.38 |
| 52-Week Range | 24.28 - 43.62 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About FRA:B6E
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy... [Read more]
Financial Performance
In 2025, FRA:B6E's revenue was 28.24 billion, an increase of 8.50% compared to the previous year's 26.03 billion. Earnings were 478.00 million, a decrease of -87.70%.
Financial numbers in SEK Financial StatementsNews
Swedish Orphan Biovitrum AB Slides: SEB Nordic Large Cap Seminar presentation
Swedish Orphan Biovitrum AB has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Swedish Orphan Biovitrum AB Earnings Call Transcript: Q2 2026
Q2 saw 29% revenue growth and a 35% adjusted EBITA margin, driven by strong performance across all regions and key products like ALTUVOCT, Doptelet, and Gamifant. The outlook for 2026 was raised, with continued pipeline progress and new launches supporting long-term growth.
Swedish Orphan Biovitrum AB Quarterly report: Q2 2026
Swedish Orphan Biovitrum AB has published its Q2 2026 quarterly earnings report on July 16, 2026.
Swedish Orphan Biovitrum AB Slides: Q2 2026
Swedish Orphan Biovitrum AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.
Swedish Orphan Biovitrum AB Earnings Call Transcript: Q1 2026
Q1 2026 saw 24% revenue growth and a 38% adjusted EBITDA margin, driven by strong launches and portfolio expansion. Key products like ALTUVOCT, Gamifant, Aspaveli, and Doptelet delivered robust growth, and the outlook for 2026 remains positive with continued investment in launches and R&D.
Swedish Orphan Biovitrum AB Quarterly report: Q1 2026
Swedish Orphan Biovitrum AB has published its Q1 2026 quarterly earnings report on April 28, 2026.
Swedish Orphan Biovitrum AB Slides: Q1 2026
Swedish Orphan Biovitrum AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, March 27, 2026 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be ...
Swedish Orphan Biovitrum AB Slides: Investor presentation
Swedish Orphan Biovitrum AB has posted slides in relation to its latest quarterly earnings report, which was published on March 6, 2026.
Swedish Orphan Biovitrum AB Transcript: CMD 2026
Ambitious plans target doubling revenue to SEK 55 billion by 2030, driven by six major product launches and global expansion. Robust R&D, digital innovation, and disciplined financial management underpin growth, with a focus on rare diseases and new therapeutic areas.
Swedish Orphan Biovitrum AB Press release: FY 2026
Swedish Orphan Biovitrum AB issued a press release on February 18, 2026, disclosing material business information to investors.
Swedish Orphan Biovitrum AB Slides: FY 2026
Swedish Orphan Biovitrum AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on February 18, 2026.
Swedish Orphan Biovitrum AB Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw robust revenue and margin growth, driven by strategic portfolio expansion and successful product launches. 2026 will be a transition year with significant investments moderating margins, but multiple high-value launches are expected to drive long-term growth.
Swedish Orphan Biovitrum AB Annual report: Q4 2025
Swedish Orphan Biovitrum AB has published its Q4 2025 annual report on February 5, 2026.
Swedish Orphan Biovitrum AB Quarterly report: Q4 2025
Swedish Orphan Biovitrum AB has published its Q4 2025 quarterly earnings report on February 5, 2026.
Swedish Orphan Biovitrum AB Slides: Q4 2025
Swedish Orphan Biovitrum AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 5, 2026.
Swedish Orphan Biovitrum AB Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong Q3 growth and a strategic portfolio now drive 64% of business, with six major launches planned through 2028. The Arthrosi acquisition and promising pipeline advances, including Gamifant in sepsis, support optimism for sustained growth.
Swedish Orphan Biovitrum AB Transcript: M&A Announcement
The acquisition brings a late-stage, best-in-class gout therapy into the portfolio, targeting a large unmet need and supporting long-term growth. The deal is structured for financial flexibility, with expected accretion to sales and earnings from 2030 onward.
Swedish Orphan Biovitrum AB Press release: M&A Announcement
Swedish Orphan Biovitrum AB issued a press release on December 15, 2025, disclosing material business information to investors.
Swedish Orphan Biovitrum AB Slides: M&A Announcement
Swedish Orphan Biovitrum AB has posted slides in relation to its latest quarterly earnings report, which was published on December 15, 2025.
Swedish Orphan Biovitrum AB Earnings Call Transcript: Q3 2025
Q3 saw 21% revenue growth and a 47% adjusted EBITDA margin, driven by strong performance in strategic products and pipeline progress. Guidance for 2025 was upgraded, with continued growth expected and investments planned for key launches. Bonjour impairment impacted net earnings.
Swedish Orphan Biovitrum AB Quarterly report: Q3 2025
Swedish Orphan Biovitrum AB has published its Q3 2025 quarterly earnings report on October 20, 2025.
Swedish Orphan Biovitrum AB Slides: Q3 2025
Swedish Orphan Biovitrum AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 20, 2025.
Swedish Orphan Biovitrum AB Transcript: FDA Announcement
NASP, a novel monthly uricase therapy for uncontrolled gout, demonstrated significant efficacy and safety in Phase 3 trials, with rapid sUA reduction, high tophi resolution, and a favorable safety profile. Regulatory submission is accepted, targeting a U.S. launch in mid-2026, with robust commercialization and supply chain plans in place.
Swedish Orphan Biovitrum AB Press release: FDA Announcement
Swedish Orphan Biovitrum AB issued a press release on September 16, 2025, disclosing material business information to investors.